Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
Dow 12,874.00 +72.81 0.57%
S&P 500 1,351.77 +9.13 0.68%
Nasdaq 2,931.39 +27.51 0.95%
Ticker Volume Price Price Delta
STOXX 50 2,491.54 +10.78 0.43%
FTSE 100 5,905.70 +53.31 0.91%
DAX 6,738.47 +45.51 0.68%
Ticker Volume Price Price Delta
Nikkei 8,978.71 -20.47 -0.23%
TOPIX 780.31 -1.37 -0.18%
Hang Seng 20,887.40 +103.54 0.50%
Gold 1,723.70 -0.07%
EUR-USD 1.3159 -0.2078%
Nasdaq 2,931.39 +0.95%
Dow 12,874.00 +0.57%
S&P 500 1,351.77 +0.68%
FTSE 100 5,905.70 +0.91%
STOXX 50 2,491.54 +0.43%
DAX 6,738.47 +0.68%
Oil (WTI) 100.64 -0.27%
U.S. 10-year 1.969% -0.017
BAC:US 8.25 +2.23%
CSCO:US 20.03 +0.68%
Live TV

Dr. Reddy's Laboratories Is in Talks to Enter Japan's Generic-Drug Market

By Adi Narayan -

Dr. Reddy’s Laboratories Ltd. is in talks to enter Japan’s generic-drug market, said S. Rajan, a company spokesman.

“We are in early stages of evaluating partnership options as part of our Japan entry strategy,” Rajan said in an e-mail today.

Dr. Reddy’s is in talks with three Japanese drugmakers to buy a stake, ET Now television channel reported yesterday, without saying where it got the information. The three companies are Towa Pharmaceutical Co., Sawai Pharmaceutical Co. and Fuji Pharma Co., the station said.

The Japanese companies denied the report in separate statements to the Tokyo Stock Exchange today.

To contact the reporter on this story: Adi Narayan in Mumbai at anarayan8@bloomberg.net

Sponsored Links

Headlines

Recommended

Most Popular

Advertisement
Sponsored Links
Advertisement
Advertisements